Company:  VERICEL CORP (VCEL)
Form Type:  DEFA14A
Filing Date:  4/10/2020 
CIK:  0000887359 
Address:  64 SIDNEY ST. 
City, State, Zip:  CAMBRIDGE, Massachusetts 02139 
Telephone:  (734) 930-5555 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$14.38  
Change: 
0.15 (1.05%)  
Trade Time: 
May 29  
Market Cap: 
$646.57M
Trade VCEL now with 

© 2020  
Description of Business
Vericel Corporation is a leader in advanced cell therapies and specialty biologics for the sports medicine and severe burn care markets. We currently have two marketed advanced cell therapy products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults that was approved by the U.S. Food and Drug Administration (FDA) on December 13, 2016. The first implantation of MACI occurred on January 31, 2017. At the end of the second quarter of 2017, we removed Carticel (autologous cultured chondrocytes), an earlier generation ACI product, from the market.
Register and access this filing in:     
  FORM DEFA14A
    SUPPLEMENT TO PROXY STATEMENT DATED MARCH 20, 2020